Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN

Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
July 02, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics’ CEO Issues Shareholder Letter

HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
June 24, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board

HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
June 17, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product

HAIFA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
May 15, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper

HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
May 06, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry

HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
April 29, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe

HAIFA, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...
April 23, 2019 08:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Issues Shareholder Update

Recent financing provides funding through multiple potentially value-creating milestonesProviding short and mid-term milestones, targeting marketing and significant contracts HAIFA, Israel, April ...
April 04, 2019 09:17 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

HAIFA, Isreal, April 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel...
April 03, 2019 16:51 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock

HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel...